Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients wth Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study Abstract #1798

Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Aim(s): CLARINET FORTE will investigate the safety and antitumour efficacy of instead using LAN 120mg/14 days.
Materials and methods: Adults with well-differentiated, metastatic/locally advanced, unresectable, functioning/non-functioning, G1/G2, pancreatic (pNETs) or midgut NETs, ECOG PS 0–2, are eligible if radiological PD (central review, RECIST v1.0) occurred with first-line LAN 120mg/28 days ≤24 months previously. Patients (pNETs, n=50; midgut NETs, n=50) will receive LAN 120mg/every 14 days up to week 48 (pNETs)/96 (midgut NETs) unless they experience PD, die or toxicity/tolerability is unacceptable. Unless 25 events occur in each cohort, visits will continue every 12 weeks until PD, death or unacceptable toxicity/tolerability. A data safety monitoring board will oversee the study (NCT02651987; EudraCT–2014-005607-24).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Marianne Pavel

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1475 Tumor Growth Rate (TGR) as an Indicator of Antitumor Activity with Lanreotide Autogel/Depot (LAN) vs Placebo (Pbo) in Intestinal/Pancreatic NET: Post Hoc Analysis of CLARINET Data
Introduction: TGR is a novel measure of tumor growth activity that may be more precise than RECIST for evaluating response to treatment of NETs.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Christine Massien
Keywords: TGR, PFS
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Dr. Markus Raderer
#2102 Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study
Introduction: TGR0 >4%/month was associated with shorter progression-free survival (PFS) in patients (pts) treated with lanreotide in the CLARINET study. Impact of TGR0 in pts treated with other systemic therapies (ST) and with Ki67>10% is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Joakim Crona
#2232 Role of Interval Reduction of Somatostatin Analogs in Patients with Progressive Neuroendocrine Tumors: Our Experience
Introduction: Interval reduction of somatostatin analogs (SSAs) is a possibly strategy for elderly patients with progressive metastatic neuroendocrine tumors (NETs). Patients with diagnosis of NET are >75 years old in the 25% of cases. No randomized studies are available to evaluate efficacy of this treatment schedule.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Ivana Puliafito